{"id":393915,"date":"2026-01-07T12:57:19","date_gmt":"2026-01-07T12:57:19","guid":{"rendered":"https:\/\/www.newsbeep.com\/ca\/393915\/"},"modified":"2026-01-07T12:57:19","modified_gmt":"2026-01-07T12:57:19","slug":"what-you-need-to-know-10","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ca\/393915\/","title":{"rendered":"What You Need to Know"},"content":{"rendered":"\n<p class=\"yf-vbsvxt\">Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products. With a market cap of\u00a0$143.2 billion,\u00a0the\u00a0company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. The pharmaceutical giant is expected to announce its fiscal\u00a0fourth-quarter earnings for 2025 before the market opens on Tuesday, Feb. 3.<\/p>\n<p class=\"yf-vbsvxt\">Ahead of the event, analysts expect PFE to report a\u00a0profit of $0.56 per share on a diluted basis, down 11.1% from\u00a0$0.63 per share in the year-ago quarter. The company has consistently surpassed Wall Street\u2019s EPS estimates in its last four quarterly reports.<\/p>\n<p class=\"yf-vbsvxt\">For the full year, analysts expect PFE to report EPS of $3.11, unchanged from the year-ago quarter. However, its EPS is expected to decline 4.8% year over year to $2.96 in fiscal 2026.<\/p>\n<p>    <img fetchpriority=\"high\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"www.barchart.com\" loading=\"eager\" height=\"587\" width=\"903\" class=\"yf-lglytj loader\"\/> www.barchart.com      <\/p>\n<p class=\"yf-vbsvxt\">PFE stock has underperformed the S&amp;P 500 Index\u2019s ($SPX)\u00a016.2% gains over the past 52 weeks, with shares\u00a0down 5.3% during this period. Similarly, it underperformed the\u00a0Health Care Select Sector SPDR Fund\u2019s (XLV)\u00a011.6% returns\u00a0over the same time frame.<\/p>\n<p>    <img decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"www.barchart.com\" loading=\"lazy\" height=\"603\" width=\"902\" class=\"yf-lglytj loader\"\/> www.barchart.com      <\/p>\n<p class=\"yf-vbsvxt\">Pfizer&#8217;s underperformance is due to worries about patent expirations for blockbuster meds like Eliquis and Ibrance, plus fading COVID-19 sales.<\/p>\n<p class=\"yf-vbsvxt\">On Nov. 4, 2025, PFE shares closed down by 1.5% after reporting its Q3 results. Its adjusted EPS of $0.87 exceeded Wall Street expectations of $0.66. The company\u2019s revenue was $16.7 billion, topping Wall Street forecasts of $16.6 billion. PFE expects full-year adjusted EPS in the range of $3 to $3.15, and expects revenue in the range of $61 billion to $64 billion.<\/p>\n<p class=\"yf-vbsvxt\">Analysts\u2019\u00a0consensus opinion on PFE stock is moderately bullish, with a \u201cModerate Buy\u201d rating overall. Out of 24 analysts covering the stock, six advise a \u201cStrong Buy\u201d rating, one suggests a \u201cModerate Buy,\u201d 16 give a \u201cHold,\u201d and one recommends a \u201cStrong Sell.\u201d PFE\u2019s average analyst price target is $27.95, indicating a potential upside of 11% from the current levels.<\/p>\n<p class=\"yf-vbsvxt\"> On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally\u00a0published on <a href=\"https:\/\/www.barchart.com\/story\/news\/36901037\/pfizer-s-quarterly-earnings-preview-what-you-need-to-know?utm_source=yahoo&amp;utm_medium=syndication&amp;utm_content=footer_link\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Barchart.com;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">Barchart.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products. With a&hellip;\n","protected":false},"author":2,"featured_media":393916,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[49,48,118208,166790,84,392,38472,166788,4470,166789],"class_list":{"0":"post-393915","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-ca","9":"tag-canada","10":"tag-eps-estimates","11":"tag-fiscal-fourth-quarter-earnings","12":"tag-health","13":"tag-healthcare","14":"tag-medical-devices","15":"tag-pfe-stock","16":"tag-pfizer-inc","17":"tag-quarterly-reports"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/393915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=393915"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/393915\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/393916"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=393915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=393915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=393915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}